June 18, 2020 / 6:43 PM / a month ago

BRIEF-Redhill Biopharma Expands Opaganib Covid-19 Phase 2/3 Study With Clinical Trial Applications In Italy And UK

June 18 (Reuters) - Redhill Biopharma Ltd:

* REDHILL BIOPHARMA EXPANDS OPAGANIB COVID-19 PHASE 2/3 STUDY WITH CLINICAL TRIAL APPLICATIONS IN ITALY AND UK

* REDHILL BIOPHARMA LTD - CLINICAL STUDY OF OPAGANIB IN UP TO 40 SEVERE COVID-19 PATIENTS HAS BEEN APPROVED BY FDA AND IS OPEN FOR RECRUITMENT IN U.S

* REDHILL BIOPHARMA - PHASE 2/3 STUDY PLANNED TO ENROLL UP TO 270 SUBJECTS WITH SEVERE COVID-19 PNEUMONIA REQUIRING HOSPITALIZATION, TREATMENT

* REDHILL - PHASE 2A STUDY WITH OPAGANIB SET TO ENROLL UP TO 40 PATIENTS WITH SEVERE COVID-19 PNEUMONIA REQUIRING HOSPITALIZATION, SUPPLEMENTAL OXYGEN

* REDHILL BIOPHARMA - CURRENTLY PLANS TO CONDUCT PHASE 2/3 STUDY IN UP TO 40 CLINICAL SITES ACROSS RUSSIA, ITALY, UK, ADDITIONAL COUNTRIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below